With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna (NASDAQ:MRNA) is planning to launch a messenger-RNA-based vaccine for skin cancer as early as next year, Japanese ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Moderna aims to reduce its research and development budget by about 20 percent over the next three years as the biotech tries to find a path to profitability following disappointing vaccine sales.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...